Filing Flows › Puma Biotechnology (PBYI) › Q2 2026 › vs Q1 2026
Puma Biotechnology (PBYI) Q2 2026 vs Q1 2026 (quarter over quarter)
Puma Biotechnology's revenue rose $11.7M (+26%) from $44.8M in Q1 2026 to $56.5M in Q2 2026. The biggest changes: Product +$11.6M (+28%); Royalty +$87K (+3%). Operating margin 13.4% against -8.5% (+22.0 pts).
Puma Biotechnology, Q2 2026: revenue $56.5M (+8% year over year), operating margin 13.4%, net earnings $8.2M, operating cash flow $1.6M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 13.4% | -8.5% | +22.0 pts |
| Net margin | 14.5% | -8.4% | +22.9 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product | $53.6M | $42.0M | $11.6M | +28% |
| Royalty | $2.9M | $2.9M | $87K | +3% |
| Revenue | $56.5M | $44.8M | $11.7M | +26% |
| Other income, net | $660K | $401K | $259K | +65% |
| Operating profit | $7.6M | −$3.8M | $11.4M | — |
| Costs & expenses | $48.9M | $48.6M | $275K | +0.6% |
| Pre-tax earnings | $8.2M | −$3.4M | $11.7M | — |
| Cost of revenue | $12.5M | $10.4M | $2.1M | +20% |
| Research & development | $18.9M | $19.8M | −$900K | -5% |
| SG&A | $17.5M | $18.4M | −$876K | -5% |
| Net earnings | $8.2M | −$3.8M | $11.9M | — |
| Income tax | $56K | $326K | −$270K | -83% |
| Operating cash sources | $12.7M | $727K | $11.9M | 17× |
| Depreciation & amortization | $2.5M | $2.6M | −$68K | -3% |
| Share-based compensation | $2.0M | $1.9M | $57K | +3% |
| Working capital & other | $11.0M | −$14.7M | $25.7M | — |
| Operating cash flow | $1.6M | $15.4M | −$13.8M | -89% |
Questions
How much did Puma Biotechnology's revenue grow quarter over quarter in Q2 2026?
Puma Biotechnology's revenue rose $11.7M (+26%) from $44.8M in Q1 2026 to $56.5M in Q2 2026.
What drove Puma Biotechnology's revenue change in Q2 2026?
Product +$11.6M (+28%); Royalty +$87K (+3%).